Greenwich LifeSciences AI Stock Analysis
Greenwich LifeSciences (GLSI) AI Stock Analysis
Greenwich LifeSciences
(NASDAQ:GLSI)
No summary available
Greenwich LifeSciences (GLSI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $290.48M
- Dividend Yield
- ―
- Average Volume (3M)
- 156.20K
- Price to Earnings (P/E)
- -12.1
- Beta (1Y)
- 1.95
- Revenue Growth
- ―
- EPS Growth
- -9.87%
- Country
- US
- Employees
- 13
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Greenwich LifeSciences Business Overview & Revenue Model
Company Description
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its fla...
Greenwich LifeSciences Risk Analysis
Greenwich LifeSciences disclosed 72 risk factors in its most recent earnings report. Greenwich LifeSciences reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksGreenwich LifeSciences Peers Comparison
Overall Rating
CGEN73Outperform
NKTX43Neutral
SKYE42Neutral
STTK42Neutral
MOLN39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | $178.09M | 4.83 | 39.30% | ― | 999.97% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $80.31M | -0.65 | -48.58% | ― | ― | -24.79% | |
| 42Neutral | $3.48M | -0.10 | -503.95% | ― | ― | 26.40% | |
| 42Neutral | $463.38M | -8.92 | -46.46% | ― | -100.00% | 50.26% | |
| 39Underperform | $103.37M | -1.60 | -79.25% | ― | ― | 11.22% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GLSI | Greenwich Lifesciences, Inc. | 19.79 | 11.94 | 152.10% | |
| CGEN | Compugen | 1.88 | 0.29 | 18.24% | |
| SKYE | Skye Bioscience, Inc. | 0.79 | -9.61 | -92.44% | |
| NKTX | Nkarta, Inc. | 1.12 | -0.67 | -37.43% | |
| STTK | Shattuck Labs, Inc. | 4.55 | 2.49 | 120.87% | |
| MOLN | Molecular Partners Ag | 2.60 | -1.40 | -34.88% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
